Edwards Lifesciences, a developer of heart valves and hemodynamic monitoring systems, has completed the acquisition of Bmeye, a privately held Amsterdam company that develops noninvasive technologies for hemodynamic monitoring in the surgical, intensive care, emergency room and cardiology settings.

Bmeye's monitoring products work with a noninvasive finger cuff to measure continuous information on cardiac output, blood pressure, fluid responsiveness and other hemodynamic parameters. Bmeye's products are approved for sale in the U.S., throughout Europe and in several other countries.

While Bmeye's products primarily have been used by clinicians outside of the hospital, over the next 18 months, Irvine, Calif.-based Edwards plans to further develop Bmeye's technology and integrate it into the Edwards EV1000 clinical platform for use in the acute care setting in hospitals.

The purchase price was EUR 32.5 million (approximately $42 million). Edwards said it expects the net earnings impact from this transaction to be immaterial in 2012, and slightly dilutive in 2013. Additional details will be provided in its 2013 financial guidance in December.